Lung Cancer and Aging in Older Adults
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at aging-related changes in older adults (70+) with early-stage lung cancer who are planning to have surgery. The goal is to better understand how these changes might affect recovery and outcomes, which could help improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older
- You have non-small cell lung cancer (NSCLC) that is early or locally advanced (stage I, II, or IIIA)
- Your doctor plans surgery to try to cure the cancer
- You do not have any other active cancer (except for basal cell skin cancer or prostate cancer treated with local therapy, like surgery or radiation)
- You are able to understand the study and give your consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests approved cancer drugs in people aged 70 and older with non-small-cell lung cancer who haven't had systemic treatment before. The goal is to see how well these drugs work in this older population.
This study looks at biological samples from people diagnosed with lung cancer at age 45 or younger. It may help researchers understand how young lung cancers differ, which could guide future treatments.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This study looks at how lung cancer changes over time by analyzing tumor tissue and blood. It may help researchers understand what drives cancer relapse after early-stage surgery.
This study tests a milder chemotherapy combined with an immunotherapy drug (anti-PD-1) as the first treatment for advanced lung cancer in older or frailer adults. It aims to see if this approach works better with fewer side effects.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.